The FDA clearances are a positive product milestone for RadNet's AI subsidiary, but the lack of revenue guidance or adoption metrics limits near-term stock impact. Monitor future earnings calls for updates on commercial deployment and any contribution to RadNet's Digital Health segment.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $60.01entry
- T+1 · 5mo ago +1.22%α +1.94% · $60.74
- T+5 · 5mo ago +9.35%α +7.79% · $65.62
- T+20 · 4mo ago +1.62%α +1.09% · $60.98
- T+60 · 8w ago +26.65%α +22.92% · $76.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
DeepHealth, a wholly owned subsidiary of RadNet (RDNT), received FDA 510(k) clearances for two new breast imaging AI functionalities: BAC Assessment (identifies breast arterial calcifications as a cardiovascular risk indicator) and Mammo Dx (prior exam integration for improved cancer detection). The clearances expand the Breast Suite but no financial terms or revenue impact were disclosed.
Key Facts
- FDA 510(k) clearance for BAC Assessment, which automatically identifies breast arterial calcifications on standard mammograms with >90% sensitivity and >88% specificity.
- FDA 510(k) clearance for Mammo Dx (formerly ProFound Pro), which integrates prior exams to track lesions and improve cancer detection rates.
- Both functionalities are now commercially available in the U.S. and will be deployed across RadNet imaging centers.
- The clearances add to DeepHealth's Breast Suite, which already includes breast density assessment, risk assessment, and workflow tools.
Financial Impact
No direct financial impact stated; potential for incremental AI licensing revenue or increased imaging volume at RadNet centers, but unquantified.
Risk Factors
- Adoption uncertainty: no disclosed contracts or revenue projections for the new AI tools.
- Competitive landscape: other AI breast imaging solutions exist (e.g., Hologic, iCAD).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3317350 |
Track record
21 reports on RDNT
0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Oct 26, 2026 report. 0 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $76.04 Now $76.42 +0.50% settles Feb 10
- Nov 9, 20267d ago 8-K Bullish 6/10 No price data
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $78.38 Now $76.42 −2.50% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $73.54 Now $76.42 +3.92% settles Jan 26
- Oct 26, 202621d ago 8-K Neutral 6/10 Entry $73.54 Now $76.42 +3.92% settles Jan 25
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $73.54 Now $76.42 +3.92% settles Jan 25
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $67.70 Now $76.42 +12.88% settles Dec 28
- Aug 10, 202614w ago 8-K Bullish 6/10 No price data
- Aug 9, 202614w ago Press Release Mixed 6/10 Entry $77.28 to $73.18 Now $76.42 −1.11% ▼ −5.31% −2.89% vs SPY
- Jun 25, 202620w ago Press Release Bullish 5/10 Viewing Entry $60.01 to $76.00 Now $76.42 +27.35% ▲ +26.65% +22.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers